Histological findings of uveal capillaries in rabbit eyes after multiple intravitreal injections of bevacizumab

References

• Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E. Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2000;41:1649–1656
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584–2586
   PubMed Web of Science ®Google Scholar
• Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372–400
   PubMed Web of Science ®Google Scholar
• Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:68–73
   PubMed Web of Science ®Google Scholar
• Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthal Surg Lasers Imaging 2007;38:233–237
   PubMedGoogle Scholar
• Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 2012 Sep 8. [Epub ahead of print]
   Google Scholar
• Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115:1571–1580
   PubMed Web of Science ®Google Scholar
• Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007;16:437–439
   PubMed Web of Science ®Google Scholar
• Korte GE, Gerszberg T, Pua F, Henkind P. Choriocapillaris atrophy after experimental destruction of the retinal pigment epithelium in the rat. A study in thin sections and vascular casts. Acta Anat (Basel) 1986;127:171–175
   PubMedGoogle Scholar
• Leonard DS, Zhang XG, Panozzo G, Sugino IK, Zarbin MA. Clinicopathologic correlation of localized retinal pigment epithelium debridement. Invest Ophthalmol Vis Sci 1997;38:1094–1109
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995–1002
   PubMed Web of Science ®Google Scholar
• Shimomura Y, Hirata A, Ishikawa S, Okinami S. Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 2009;247:1089–1094
   PubMed Web of Science ®Google Scholar
• Hogan MJ, Alvarado JA, Weddell JE. Choroid: in histology of the human eye. Philadelphia: W.B. Saunders; 1971
   Google Scholar
• Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155:421–428
   PubMed Web of Science ®Google Scholar
• Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451–1459
   PubMed Web of Science ®Google Scholar
• Pappas GD, Tennyson VM. An electron microscopic study of the passage of colloidal particles from the blood vessels of the ciliary processes and choroid plexus of the rabbit. J Cell Biol 1962;15:227–239
   PubMed Web of Science ®Google Scholar
• Daitoku D, Kurose T, Mori E, Hashimoto M, Kawamata S. Changes in the rat subcutaneous connective tissue after saline and histamine injection in relation to fluid storage and excretion. Arch Histol Cytol 2007;70:29–41
   PubMedGoogle Scholar
• Sugimoto Y, Mochizuki H, Okumichi H, Takumida M, Takamatsu M, Kawamata S, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2010;248:1601–1609
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162–164
   PubMed Web of Science ®Google Scholar
• Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007;91:1230–1233
   PubMed Web of Science ®Google Scholar
• Karawya S, Said DG, Salaheldin MM, Zaky I. Impact of intravitreal injection of bevacizumab (Avastin) on rabbit's choroid and retina. Middle East Afr J Ophthalmol 2008;15:67–72
   PubMedGoogle Scholar
• Maruko I, Iida T, Sugano Y, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopaty. Retina 2011;31:1603–1608
   PubMed Web of Science ®Google Scholar
• Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, Humayun MS. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 2007;48:5708–5715
   PubMed Web of Science ®Google Scholar
• Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, et al. Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009;50:1659–1665
   PubMed Web of Science ®Google Scholar
• Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008;115:1750–1755, 1755 e1751
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855–859
   PubMed Web of Science ®Google Scholar
• Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508–512
   PubMed Web of Science ®Google Scholar
• Sasamoto Y, Oshima Y, Miki A, Wakabayashi T, Song D, Matsushita K, et al. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study. J Ocul Pharmacol Ther 2012;28:41–48
   PubMed Web of Science ®Google Scholar